PHARMACY

FDA panel declines to recommend new approval for J&J anticlotting drug

BY Alaric DeArment

RARITAN, N.J. — A Food and Drug Administration expert panel has recommended against expanding the approval of a Johnson & Johnson drug, the company said.

J&J subsidiary Janssen Research & Development said the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted against recommending approval of Xarelto (rivaroxaban) combined with antiplatelet drugs to reduce the risk of secondary cardiovascular events in patients with acute coronary syndrome.

The FDA is not required to follow the recommendations of advisory committees, but usually does. Xarelto already is approved for reducing the risk of blood clots in patients who have had knee or hip replacement surgery and for reducing the risk of strokes and other blood clots in certain people with atrial fibrillation.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Endo parent company changes name to Endo Health Solutions Inc.

BY Alaric DeArment

CHADDS FORD, Pa. — The parent company of Endo Pharmaceuticals has changed its name, the company said.

Shareholders of Endo Pharmaceutical Holdings voted at the company’s annual shareholder meeting Wednesday to change the company’s name to Endo Health Solutions. The company said the name change would more accurately reflect its new business model, which aggregates four operating businesses into one enterprise.

"This important decision by our shareholders marks a milestone in our company’s history and reinforces our position in the market as a leading provider of health solutions, merging healthcare information and a broader array of innovative treatment options that can ultimately lead to improved health outcomes for patients," Endo president and CEO Dave Holveck said.

The company’s new business model will include four segments: medical device developer AMS; branded drug division Endo Pharmaceuticals; medical services, software, laboratory and medical records technology provider HealthTronics; and generic drug maker Qualitest.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Rexam teams up with Marsh, MainStreet Market pharmacies to offer safe Rx disposal

BY Allison Cerra

PERRYSBURG, Ohio — Rexam Prescription Products recently partnered with Marsh and MainStreet Market pharmacies for a new campaign that encourages consumers to safely dispose of their unused or expired medications.

The "Clean Out Your Medicine Cabinet" campaign encouraged consumers could bring their leftover medications to one of 40 Marsh Pharmacy and MainStreet Market Pharmacy locations throughout Indiana for free and safe disposal. More than 37,000 vials were collected over a 4-day period and were properly disposed through a local incinerator. Marsh first began hosting "clean out" events in 2008, and since that time has collected more than 140,000 vials of unused medications.

"We are pleased to partner with Marsh and support their efforts to improve prescription disposal," said Pat O’Connell, Rexam’s VP sales and marketing for prescription products. “It’s another example of how we work closely with our customers to address industry issues and add value to consumers’ lives."

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES